Lisa Sanders, director of science and technology for Special Operations Forces, acquisition, technology & logistics (SOF AT&L), told the outlet that SOCOM has completed pre-clinical safety and “dosing studies in anticipation of follow-on performance testing” of the drug, which has the potential to “delay aging” and “prevent onset of injury.”
h/t Marvin
